Table 2. Association between ELAC2 staining and prostate cancer phenotype in the TMPRSS2: ERG fusion negative subset.

Parameter	Evaluable	ELAC2 nuclear staining (%)				P value
	(n)	Negative	Weak	Moderate	Strong
Total	4 521	48.7	24.0	21.0	6.2
Tumor stage
pT2	3 027	52.2	23.4	19.7	4.7	<0.0001
pT3a	914	46.3	25.4	21.2	7.1
pT3b	543	33.1	25.8	28.2	12.9
pT4	23	47.8	13.0	30.4	8.7
Gleason grade
≤3+3	959	65.8	19.7	12.6	1.9	<0.0001
3+4	2 359	48.2	24.8	21.4	5.6
3+4 Tert.5	189	36.5	27.0	26.5	10.1
4+3	490	40.6	27.3	23.3	8.8
4+3 Tert.5	261	29.9	24.5	32.2	13.4
≥4+4	260	33.5	23.8	30.0	12.7
Lymph node metastasis
N0	2 613	45.5	25.0	22.2	7.3	<0.0001
N+	255	31.4	23.9	31.4	13.3
Preoperative PSA level (ng/ml)
<4	461	46.0	24.5	20.8	8.7	0.0053
4–10	2 663	49.6	23.8	21.2	5.4
10–20	992	46.8	25.2	22.2	5.8
>20	366	50.0	21.9	17.5	10.7
Surgical margin
Negative	3 586	49.3	23.8	20.8	6.1	0.4911
Positive	855	46.8	23.9	22.7	6.7